In a double-blind study, nirmatrelvir-ritonavir treatment (Paxlovid) reduced risk for hospitalization and death risk by 89% vs placebo among high-risk adults infected with COVID-19 who were not hospitalized when administered with 3 days of symptom onset. No deaths were reported among patients who received ritonavir in the overall study population through day 28 compared with the placebo group, in which 10 deaths occurred.
Learn more about nirmatrelvir-ritonavir.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: COVID Treatments - Medscape - Mar 01, 2022.